• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management

    2020-06-17 10:22:58MajaCigrovskiBerkovicLucijaVirovicJukicInesBilicCurcicAnnaMrzljak
    World Journal of Gastroenterology 2020年21期

    Maja Cigrovski Berkovic, Lucija Virovic-Jukic, Ines Bilic-Curcic, Anna Mrzljak

    Abstract Liver cirrhosis and diabetes mellitus (DM) are both common conditions with significant socioeconomic burden and impact on morbidity and mortality. A bidirectional relationship exists between DM and liver cirrhosis regarding both etiology and disease-related complications. Type 2 DM (T2DM) is a wellrecognized risk factor for chronic liver disease and vice-versa, DM may develop as a complication of cirrhosis, irrespective of its etiology. Liver transplantation(LT) represents an important treatment option for patients with end-stage liver disease due to non-alcoholic fatty liver disease (NAFLD), which represents a hepatic manifestation of metabolic syndrome and a common complication of T2DM. The metabolic risk factors including immunosuppressive drugs, can contribute to persistent or de novo development of DM and NAFLD after LT.T2DM, obesity, cardiovascular morbidities and renal impairment, frequently associated with metabolic syndrome and NAFLD, may have negative impact on short and long-term outcomes following LT. The treatment of DM in the context of chronic liver disease and post-transplant is challenging, but new emerging therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) targeting multiple mechanisms in the shared pathophysiology of disorders such as oxidative stress and chronic inflammation are a promising tool in future patient management.

    Key words: Diabetes mellitus; Liver transplantation; Non-alcoholic fatty liver disease;Metabolic syndrome; Insulin-resistance; Glucagon-like peptide-1 receptor agonists;Sodium-glucose cotransporter 2 inhibitors

    INTRODUCTION

    Diabetes mellitus (DM) represents a group of heterogeneous diseases caused by an impaired insulin secretion and/or action. It is characterized by hyperglycemia and derangements in carbohydrate, lipid and protein metabolism, causing the development of numerous complications resulting in increased morbidity and mortality of patients[1]. According to the World Health Organization data, 422 million adults live with DM worldwide and global prevalence is estimated to rise to 592 million by 2035[2,3].

    The liver has a key role in glucose metabolism. It is responsible for the maintenance of total carbohydrate stores and for gluconeogenesis. Regulation of the complex and interdependent glycolytic-gluconeogenic pathways is dependent on multiple factors,including hormonal status and the relative availability of nutrient substrates[4].

    The association between DM and liver disease is well established and complex in nature. Insulin resistance (IR) and type 2 DM (T2DM) within the metabolic syndrome are important risk factors for the development of non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)[5]. On the other hand, liver cirrhosis of any etiology can cause impaired glucose regulation due to diminished liver function, and the term hepatogenous diabetes has been proposed for this entity[6,7]. However, it is sometimes difficult to establish this diagnosis, due to the aforementioned bidirectional relationship between impaired glucose metabolism and chronic liver disease.

    Liver transplantation (LT) is a well-established treatment option for end-stage liver disease of any etiology. Following LT, glucose metabolism can improve and DM resolve, especially in patients with diabetes following liver cirrhosis development.However, this may not be true for patients with pre-existing diabetes, and to further complicate this relationship, DM may develop post-transplant, due to genetic factors and lifestyle changes of the patient, immunosuppressive treatment, donor-dependent and procedure-related factors (Figure 1).

    The complex relationship and mechanisms involved in the interplay between DM and liver disease before and after LT will be explored, and related to management issues, newer treatment options and patient outcomes.

    NAFLD

    The global prevalence of metabolic syndrome characterized by the morbidity cluster of obesity, T2DM, hypertension and dyslipidemia is rapidly rising, reflecting the changes in eating habits and inclination towards sedentary lifestyle. In parallel, its liver manifestation NAFLD is becoming the most common cause of chronic liver disease and the leading cause of liver-related mortality[8]. The global prevalence of NAFLD is now estimated around 25%, the highest being in South America and in the Middle East (30%-31%) and the lowest in Africa (13%)[9].

    Figure 1 A complex relationship between liver disease and diabetes mellitus. Although in case of diabetes mellitus following liver cirrhosis glycemia might improve after liver transplantation (LT), this may not be the case in the preexisting type 2 diabetes mellitus. Moreover, diabetes can develop following LT (posttransplant diabetes mellitus) due to different patient and procedure-related factors. Both diabetes and liver disease after transplant increase the cardiovascular risk,which is the main cause of mortality in the long-term follow-up. LT: Liver transplantation; HCC: Hepatocellular carcinoma; PTDM: Post-transplant diabetes mellitus; IR:Insulin resistance; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.

    NAFLD encompasses a wide spectrum of histological changes in the liver, ranging from simple steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis, fibrosis and finally cirrhosis[10]. Approximately 25% of NAFLD patients develop NASH, and 5% progress to cirrhosis. Severe liver-related events,such as death or need for LT are relatively uncommon, and occur in 1-2% of patients with NAFLD. However, given its high global prevalence, NAFLD has become the fastest growing indication for LT[11].

    The pathogenesis of NAFLD is multifactorial and complex, with multiple mechanisms involved in the development and progression of the disease[12,13]. Genetic factors, dietary habits and other environmental factors lead to obesity and insulin resistance (IR), which is the key mechanism responsible for the NAFLD forming cascade of events. Impaired inhibition of adipose tissue lipolysis with consequent increased influx of free fatty acids into the liver together with increased hepaticde novolipogenesis outweigh fatty acid oxidation and triglyceride secretion, resulting in the accumulation of triglycerides in hepatocytes[12,13]. Increased lipotoxicity causes mitochondrial dysfunction, oxidative stress and production of reactive oxygen species; these changes result in a more severe form of NASH[14]. Obesity and insulin resistance are associated with alterations in gut microbiota and changes in intestinal permeability with consequent activation of inflammatory pathways and release of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin 1 and 6[12,13]. Changes in the secretion of adipokines, hormones derived from adipose tissue,such as adiponectin, leptin, resistin or ghrelin, contribute to chronic inflammatory state which consequently leads to further liver injury, where long-standing liver damage and repair responses result in activation of hepatic stellate cells and deposition of fibrous matrix, leading to cirrhosis and development of HCC[15,16].However, although steatosis in NAFLD usually precedes inflammation, it has been recognized that hepatic inflammation and fibrosis can exist without steatosis[12,17].Numerous and diverse processes which contribute to the development of steatosis and liver inflammation occur in parallel, and it is possible that different risk of progression of simple steatosis or NASH to more advanced liver disease may actually allude that these two are separate entities in terms of pathogenesis[12,17].

    Given the high burden of NAFLD and its consequences, end-stage liver disease and HCC, NAFLD represents a growing indication for LT both in Europe and the United States. In the near future, the prevalence of NAFLD as indication for LT is expected to rise due to increasing prevalence of obesity, T2DM and metabolic syndrome, but also because of lack of symptoms and reliable non-invasive tests for the timely and accurate diagnosis, as well as lack of effective treatment options that could significantly alter the course of the disease. The problem is augmented by the reportedly high rates of NAFLD recurrence after LT, ranging between 30%-100% of NAFLD liver transplant recipients, andde novooccurrence of NAFLD in 20%-30% of patients undergoing LT for other indications[18-20].

    DM AND NAFLD - CARDIOVASCULAR DISEASE EQUIVALENTS?

    T2DM is an important risk factor for the development of NAFLD, and vice versa.NAFLD is associated with up to five-fold increased risk of T2DM[21]. The prevalence of DM is higher (48.4%) in NASH than in other indications waitlisted for LT. Moreover,NASH patients are more likely to be white, female, older, and with higher body mass index[22]. Concomitant NAFLD in patients with diabetes often compromises achievement of desired glycemic targets and moreover aggravates complications such as chronic kidney disease by almost 2-fold; these factors later on contribute to overall poor treatment outcomes[23,24].

    Available evidence suggests an intimate relationship between NAFLD/NASH,T2DM, cardiovascular disease (CVD) and chronic kidney disease[25]. This is not a surprise since NAFLD/NASH and T2DM share many metabolic risk factors with cardiovascular and chronic kidney disease, such as insulin resistance, atherogenic dyslipidaemia, hypertension and obesity. Different pathophysiological mechanisms have been described that contribute to CVD and chronic kidney disease development in patients with NAFLD/NASH and T2DM and this topic has been extensively reviewed elsewhere[25-27]. Although epidemiological evidence from many primarily cross-sectional, case-control and retrospective studies involving NAFLD patients with and without diabetes have shown an increased prevalence of CVD and chronic kidney disease, the complex interplay between the traditional cardiometabolic risk factors makes a causal relationship between NAFLD, T2DM, and cardiovascular and chronic kidney disease sometimes difficult to establish[28,29]. In the Multi-Ethnic Study of Atherosclerosis (MESA), NAFLD proved as independent risk factor for latent atherosclerosis, chronic inflammation and coronary artery calcium scores[30]. Similarly in the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD), the fatty liver index was a predictor of incident CVD in the middle-aged men over a median of 17-year follow-up[31]. In addition, data coming from observational studies showed the association between NAFLD and significant increase in the risk of incident chronic kidney disease[32].

    DM AND LIVER CIRRHOSIS

    Liver cirrhosis represents the end-stage liver disease caused by various etiologies and mechanisms of liver injury that lead to inflammation, necrosis, and consequent fibrogenesis. It is an important cause of morbidity and mortality worldwide, with significant regional differences in both the prevalence and etiology of the disease.Cirrhosis represents the 14th most common cause of death in adults and results in 1.03 million deaths per year[33].

    T2DM and IR are important risk factors for the development of NAFLD and NASH, which can progress to liver cirrhosis. On the other hand, IR and hyperinsulinemia are common features in cirrhosis[6,34]. Recent studies using current criteria for DM diagnosis have shown that, based on fasting plasma glucose levels,alone or associated with measurements of hemoglobin (Hb) A1c, prevalence of DM in cirrhotic individuals is approximately 30%-40%, but if individuals were subjected to an oral glucose tolerance test, the prevalence of abnormal glucose tolerance and DM would rise up to 96%[35].

    Although it has been recognized that liver cirrhosis of any etiology represents a risk factor for the development of DM, the mechanisms responsible for the development of cirrhosis-associated DM are multiple and not completely understood[6,7]. A body of evidence suggests that liver dysfunction in cirrhosis directly affects insulin secretion,clearance and insulin sensitivity, but certain etiological agents may cause IR in the earlier, pre-cirrhotic stages, through various mechanisms[6,36-39].

    Numerous epidemiological, clinical and experimental studies have reported hepatitis C virus to be strongly associated with hepatic steatosis, IR and T2DM, even before cirrhosis development[40]. HCV induces IR in the liver and peripheral tissues through multiple mechanisms. A large meta-analysis of 34 studies confirmed a positive correlation between HCV infection and increased risk of T2DM in comparison to the general population[41,42]. The prevalence of T2DM was also reported to be higher in patients with chronic hepatitis caused by HCV compared to subjects with chronic liver diseases from other etiologies[6,43]. However, prevalence of T2DM was higher in HCV infected patients following cirrhosis development, compared to earlier stages of fibrosis, and was similar to patients with cirrhosis of other etiologies,thus suggesting that diabetogenic potential of liver dysfunction was even higher than that of hepatitis C virus itself[6]. HCV related IR and steatosis appear to be associated with progression of fibrosis and development of hepatocellular carcinoma[40].

    Alcohol is known to reduce insulin-mediated glucose uptake upon acute ingestion,although the effects of chronic alcohol intake are less well understood[44]. Patients with chronic consumption of alcohol frequently suffer from chronic pancreatitis and damage to pancreatic islet β-cells can result in diabetes development[44]. The risk of developing DM seems to be related to the amount of alcohol ingested and increased twofold in persons with high alcohol intake compared to those with moderate intake[45]. Prevalence of diabetes among patients with alcohol-related liver cirrhosis according to studies ranges between 10% and 40%, with an average prevalence of around 27%[46].

    Hereditary haemochromatosis is a metabolic disorder characterized by iron accumulation and deposition in several organs. Haemochromatosis as well as alcohol consumption induce iron deposition in the liver which could interfere with the ability of insulin to suppress hepatic gluconeogenesis. However, the pathogenesis of diabetes due to haemochromatosis has also been related to concomitant injury of pancreatic βcells caused by iron deposits[6]. For this reason DM represents a clinical manifestation of haemochromatosis, and can be found in 40% do 85% of patients in advanced stages[44,47,48].

    Unlike chronic HCV infection, the relationship between hepatitis B virus infection(HBV) and insulin resistance has not been completely understood as the studies produced conflicting results[49]. However, most studies concur that the incidence of DM in patients with HBV infection is not increased compared to patients without infection indicating that HBV may not influence the development of DM[49]. However,a meta-analysis comprising results of 15 studies found that the prevalence of T2DM among HBV infected patients was 1.3 times higher and concluded that chronic HBV infection does increase the risk of T2DM development[50]. The prevalence of DM is higher among patients with HBV who developed cirrhosis (22.2%), compared to those without cirrhosis (12.8%)[51]. The pooled prevalence of DM in patients with HBVrelated cirrhosis was around 22.2% (ranging from 9.4% to 35.0% in various studies)[46].This was significantly lower than in patients with cirrhosis related to NAFLD which had the highest prevalence of DM (a pooled estimate of 56.1%), or alcohol-related,HCV or cryptogenic cirrhosis (estimated prevalence ranging from 27.3% to 50.8%).The lowest prevalence of DM was found in patients with cirrhosis secondary to cholestatic liver disease (overall 7.1%, ranging from 1.3% to 15.2%)[46].

    Regardless of the etiology of cirrhosis, and irrespective of which developed first,when cirrhosis and DM coexist, they interfere with each other with reflection on course of the disease. In a population-based Italian study, the risk of death from cirrhosis was significantly higher among patients with DM[52]. A number of prospective and retrospective studies indicated that complications of liver disease(spontaneous bacterial peritonitis and other bacterial infections, ascites, hepatic encephalopathy, and gastrointestinal hemorrhage) as well as death rates are higher in cirrhotic patients with DM compared to non-diabetic patients with advanced liver disease[6]. Moreover, DM associated with poor glycemic control (HbA1c > 9%) is an independent risk factor for development of HCC in patients with chronic liver disease[53]although poor glycemic control in cirrhotic patients is not necessarily reflected through high HbA1c, but rather higher glucovariability[54]. Therefore, both uncontrolled and controlled T2DM as well as glucose intolerance can negatively impact survival of patients with liver cirrhosis[52,55]. The mechanisms involved are still not clear. Plausible explanation is that insulin resistance alone, even without the element of hyperglycemia increases adipokine production through chronic inflammation, such as leptin and TNF alpha leading to activation of TGF beta1, a profibrotic cytokine in turn activating hepatic stellate cells to produce high quantities of collagen and extracelullar matrix proteins. Of course, all these unfavorable effects of chronic inflammation mediated through IR are then largely potentiated by chronic hyperglycemia[56-61].

    POST-TRANSPLANT DM

    Post-transplant DM (PTDM) has been recognized as a major complication after LT with the potential for serious consequences and ultimately worse patient and graft survival[62]. It seems that in case of LT, the onset of PTDM is rapid; 50% of cases occurring within first 6 months and 75% after 12 mo following procedure[63]. Although IR and DM related to liver dysfunction and cirrhosis can improve following LT, the presence of metabolic syndrome and extrahepatic comorbidities, as well as immunosuppressive drugs can contribute to persistent orde novoDM following LT. It occurs in 7%-45% of liver transplant recipients and is associated with increased morbidity, health care costs and impairs both patient and graft survival[62-64]. So far,parameters such as advanced age, ethnicity, family history, body mass index, hepatitis C virus infection and immunosuppressive drugs (mainly corticosteroids and tacrolimus) have all been reported as risk factors for PTDM after LT[65,66]. Moreover,obesity, either predating or gained after transplantation, is associated with an increased risk for PTDM but also post-transplant NAFLD[67]. According to 2014 International Consensus Meeting diagnosis of PTDM can be established in patients after achieving stable doses of maintenance immunosuppressants, with stable allograft function, once they have been discharged from the hospital to avoid misdiagnosis of transient hyperglycemia[64]. Preferred criteria to diagnose PTDM(either fasting plasma glucose > 7 mmol/L, random plasma glucose > 11.1 mmol/L accompanied by symptoms or 2-hour post 75g oral glucose test plasma glucose > 11.1 mmol/L) are those of American Diabetes Association/World Health Organization criteria for the diagnosis of diabetes, and HbA1c > 6.5% should not be used alone to screen for PTDM within the first year after transplant.

    As we enter an era where recurrent hepatitis C after LT becomes a rare entity andde novoor recurrent NAFLD increases in incidence, we are likely to see changes in the patterns of incidence and impact of PTDM. Current data suggest that PTDM increases the risk of infection, chronic renal failure, biliary complications and decreases survival[68,69]. Poor LT outcomes seem not only to be related to PTDM, but also to much earlier derangements in the pathophysiology of hyperglycemia, during IR stage[70].Still, nearly 30% of deaths in LT patients are caused by cardiovascular or cerebrovascular diseases[71].

    NAFLD AFTER LT

    After LT, NAFLD/NASH may re-occur or developde novo. Histological features of recurrent orde novoNAFLD/NASH are the same as in native livers, and there are no features to differentiate recurrent fromde novoNAFLD/NASH in the graft. The diagnosis is based on correctly identifying preexisting liver disease - NASH-related or in some cases cryptogenic cirrhosis[72]. The studies assessing NAFLD recurrence after LT report a wide range from 10 to 100%[19,20,73-75]. However, regardless of indication for LT, risk factors for metabolic syndrome and NAFLD increase over time in the posttransplant setting[76,77]. Side-effects of immunosuppressive medications and rapid weight gain in the post-transplant period can lead to impaired glucose control,dyslipidemia, development of metabolic syndrome andde novoNAFLD. In fact, it has been reported in 20%-30% of patients following LT for non-NAFLD/NASH etiologies[18,19]. Weight gain is common in patients following LT and 30%-60% of patients become overweight or obese, with a mean weight gain of 2-9 kg usually within the first year after LT. After one year post-LT, weight gain typically slows down[18,78-81]. Obesity appears to be one of the strongest risk factors for the development of NAFLD in the post-transplant period[18,20]. Moreover obese patients after LT have a 2-fold higher risk of mortality compared to normal weight LT recipients[82]. The mechanisms leading to a post-transplant weight gain are driven by a complex interaction of genetic, physiological, behavioral, and environmental factors[83,84]. Dyslipidemia and hypertension occur in 40%-70% of patients, usually related to use of mammalian target of rapamycin (mTOR) inhibitors and calcineurin inhibitors. Metabolic syndrome has been reported in 40%-50% of patients after LT,both in patients with previous NAFLD as well as other etiologies of chronic liver disease. In a recent report from Mayo Clinic, 84.6% of patients hadde novoallograft steatosis and 15.4% recurrent NAFLD after 2 months post-liver transplant. After 10 years, 48% of liver transplant recipients had evidence of allograft steatosis, including 77.6% of patients transplanted for NASH and 44.7% of individuals transplanted for other indications[20]. Interestingly, in this study allograft steatosis was not associated with worse outcomes regarding graft and patient survival. However, the incidence of cardiovascular events 5 years post-transplant was approximately 40% in patients transplanted for NASH compared to 5%-10% incidence in LT recipients transplanted for non-NASH etiologies, regardless of graft steatosis[20]. This could suggest that impaired metabolic profile before LT could have more significant impact on CV events and outcomes than the post-transplant NAFLD itself. However, the long-term outcomes and consequences of complex interplay between T2DM, obesity, metabolic syndrome, pre- and post-liver transplant NAFLD with CV events require further investigation and explanation.

    T2DM TREATMENT IN THE CONTEXT OF NAFLD

    Treating type 2 diabetes, although now with available wide range of armamentarium,still remains challenging, especially in the presence of coexisting NAFLD and obesity.Acknowledging the fact that NAFLD and T2DM act synergistically in driving adverse outcomes, in the way that the NAFLD accelerates the development of diabetic chronic micro- and macrovascular complications, while the diabetes increases the likelihood of more severe forms of NAFLD such as steatohepatitis, cirrhosis, and HCC could be an important issue in choosing the treatment modality and pharmacological agent[24,85-89]. Therefore, when taking into account pathophysiology, treating NAFLD/NASH could prevent T2DM development and/or progression, but, also the other way around[90].

    As there is no specific pharmacotherapy yet available for treating NAFLD, antidiabetic drugs with pleiotropic effects, targeting multiple metabolic disorders, seem promising. Among them, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are recognized by American Diabetes Association (ADA) and European Association for Study of Diabetes (EASD)as the best treatment option for patients with T2DM and cardiovascular disease, heart failure and/or chronic kidney disease. These two classes of drugs both exert weight loosing effect, making them especially interesting for patients with associated obesity,and according to results of both randomized controlled trials (RCTs) and open-label studies, offer promising effects in reducing liver fat content[91].

    Previously used agents such as metformin and thiazolidinediones (TZDs), affecting insulin resistance, did show benefit on biochemical and metabolic features of NAFLD,but improvement of patients’ histological response or fibrosis was modest and studies were usually short-term therefore lacking information on liver-related long-term outcomes. Moreover, side-effects usually override their wider use in NAFLD patients[92-95]. Especially interesting results came from studies with NASH patients receiving TZDs. Mentioned agents activate the nuclear receptor of peroxisome proliferator-activated receptor gamma (PPARγ) located in adipose, liver and muscle tissue and exert insulin-sensitizing activity. Additionally, TZDs increase adiponectin,reduce liver fat content and modulate intra hepatic inflammation[94]. Recently published large cohort study in Taiwan using propensity score matching suggested patients with newly diagnosed T2DM receiving either rosiglitazone (not widely used anymore due to associated increased CV risk) or pioglitazone for mean of 3.84 years,compared to newly diagnosed T2DM patients that were non-TZD users, had lower risk of hepatic cirrhosis (incidence rate: 0.77vs1.95 per 1000 person-y)[96].

    One of the newer therapeutic modalities that needs to be addressed is certainly pretransplant bariatric surgery in the obese patients with or without diabetes. So far,available data for this particular subset of patients are scarce and data from randomized clinical trials are lacking. However two major points should be considered regarding bariatric procedure in liver transplant (LT) - timing and type of procedure. In a study including 37 patients who underwent LT, and 7 who underwent LT combined with sleeve gastrectomy (SG), majority of patients with LT alone had weight gain to BMI > 35, post-LT diabetes and steatosis with 3 deaths and 3 grafts losses as compared to patients undergoing the combined procedure, who had no graft losses and there were no developed post-LT DM or steatosis, with significant weight loss (mean BMI = 29) after 12 months of follow up. One patient developed a leak from the gastric staple line, and one had excess weight loss. Average time from SG to LT was 17 months[97]. This was confirmed in other study performed in liver and kidney transplant patients who underwent SG 16 months before transplant[98]. There are also some small studies available investigating SG after solid organ transplant showing favorable outcomes regarding weight loss and PTDM incidence[99-101].

    In a large cohort study comparing in-hospital mortality and length of stay for patients with no cirrhosis, compensated cirrhosis, and decompensated cirrhosis, who underwent bariatric surgery, patients with decompensated cirrhosis had highest postoperative mortality rate compared to those with compensated and non-cirrhosis patients (16.3%vs0.9% and 0.3%, respectively,P= 0.0002)[102].

    Therefore, we can conclude that sleeve gastrectomy is procedure of choice in liver transplant patients with compensated liver cirrhosis since it does not affect absorption compared to other operative modalities and provides beneficial effects in terms of weight reduction, development of PTDM and liver steatosis.

    GLP-1RA IN THE TREATMENT OF T2DM

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a newer class of antidiabetic medications with a spectrum of beneficial metabolic effects. Besides improving glycaemia by promoting glucose-dependent insulin secretion and inhibition of glucagon secretion, these agents promote weight loss by increasing satiety through central nervous system, delaying gastric emptying and potentially increasing thermogenesis in brown fat tissue. Moreover, GLP-1RAs have proven cardiovascular safety, while some representatives of the class have shown additional cardiovascular benefits/protection in large cardiovascular outcome trials[103-106].

    Although receptors for the GLP-1 on the hepatocytes are still a matter of scientific dispute, they appear to have a direct effect on the lipid metabolism of hepatocytes,which leads to reduction of hepatic steatosis and their potential in NAFLD treatment[107-110]. Of additional interest in NAFLD treatment would be their lipidlowering and anti-inflammatory potential[111,112].

    GLP-1RA IN THE TREATMENT OF NAFLD

    In patients with NAFLD intrahepatic triglyceride accumulates, while hepatic as well as muscle insulin sensitivity declines, which correlates with the IR at the adipose tissue level and its dysfunction. This was a scientific context for assessing the potential of GLP-1Ras in the treatment of NAFLD/NASH from which optimistic results showing reduction in liver enzymes and intrahepatic triglycerides content in patients with T2DM first came[113-116]. It seems that GLP-1RA inhibit dysfunctional endoplasmic reticulum stress response to fatty-acids in hepatocytes and therefore provide protective effects on hepatocytes[110]. In human studies including exenatide (5-10 μg/d) improvements in weight, body mass index, glycemic control, liver enzymes,hsCRP (high-sensitivity C-reactive protein) and adiponectin were seen in patients with ultrasound diagnosed NAFLD treated with GLP-1RA compared to metformin[117], Table 1.

    Moreover, smaller studies suggested beneficial effects of exenatide and liraglutide on liver histology[118-120]. Regarding short acting GLP-1RA lixisenatide, studies in obese or overweight T2DM patients reported increase in the proportion of patients achieving normalization of ALT[121], but there is no data on lixisenatide effects on hepatic steatosis or fibrosis.

    The first RCT confirming the efficacy of GLP-1RA in the resolution of NASH in patients with biopsy-proven diagnosis was the LEAN trial (Liraglutide Efficacy and Action in NASH) which followed patients for 48 weeks while taking liraglutide 1.8 mg daily[122]. Resolution was achieved in 39% of patients in the active arm compared with 2/22 (9%) participants in the placebo group. It seems that the improvements in liver fat were greater with prolonged duration of liraglutide treatment[119,123-126].

    Similar results were suggested in the recently published large scale RCT with semaglutide, a once weekly GLP-1RA including patients with biopsy-proven NASH[127]. There is currently no published data available on oral form of semaglutide regarding the effect on NAFLD/NASH, although it shows superiority over liraglutide in terms of weight loss[128,129].

    Another long acting GLP-1RA with a once weekly dosing, dulaglutide, according to results of a Japanese retrospective case series study, and results from the AWARD(Assessment of Weekly Administration of LY2189265 (dulaglutide) in Diabetes)development program seems promising for NASH patients in terms of reduction of liver enzymes and liver stiffness (measured by transient elastography)[130,131]. So far, no data is available for albiglutide (another once weekly administered GLP-1 RA) on NAFLD/NASH features.

    SGLT2i IN THE TREATMENT OF T2DM

    Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used oral anti diabetic agents targeting hyperglycemia in an untraditional way, by enhancing glycosuria(with the daily glucose loss ranging between 60 and 80 g). In addition to blood glucose lowering effect, glycosuria also enhances calorie loss (240-320 kcal) and thus gliflozins exert a clinically significant weight-lowering effect. Moreover, their osmotic diuretic and natriuretic effects contribute to plasma volume contraction, and decreasein both systolic and diastolic blood pressures. In the large, recently published cardiovascular outcome trials (EMPA-REG OUTCOME trial with empagliflozin,CANVAS Program with canagliflozin, DECLARE-TIMI 58 with dapagliflozin) SGLT2i proved cardiovascular benefits, primarily seen through the reduction of heart failure risk and studies assessing their renal protective effects are on their way[132-134].

    Table 1 Proven and possible effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in diabetes and metabolism-associated fatty liver disease before and after liver transplantation

    SGLT2i IN THE TREATMENT OF NAFLD

    SGLT2 inhibitors as a class have shown promising results in open-label studies and RTCs in reducing liver fat[92,135,136]. Majority of mentioned studies used biochemical markers, but some also employed different imaging techniques for assessing fatty liver content and fibrosis, while one small pilot study conducted liver biopsy to determine the hepatic effects of SGLT2 use[137-140]. Gliflozins were effective in reducing liver enzymes in diabetic patients, and more pronounced results were seen in those with accompanying NAFLD[141]. The mechanisms underlying the improvement of NAFLD with SGLT2 inhibitors remain unknown and can only be speculated, Table 1.

    It seems that SGLT2 inhibitors, compared to other oral antidiabetic agents with comparable glycemic control, offer more pronounced reductions in serum liver enzymes[142]. Mentioned effect, exceeding glucose-lowering activity, relies on other mechanisms including reduction of body weight and body fat, reduction of serum uric acid, oxidative stress and inflammation which might prove important in NAFLD treatment[143-147].

    PTDM IN LT PATIENTS AND THE ROLE OF GLP-1RA

    There are no specific guidelines for treatment of PTDM thus general recommendations for diabetes management are followed due to paucity of data regarding usage of antihyperglycemic drugs in transplanted patients.

    The main challenge in treatment of post-transplant diabetes is increased cardiovascular risk observed in patients after solid organ transplantation[148]. Due to severe metabolic disturbances caused by weight gain after transplantation and immunosuppressant drugs incidence of cardiovascular events is higher than in nontransplant patients and are the leading cause of mortality[149]. Given that recent data from large cardiovascular outcome trials demonstrated cardiovascular benefits for majority of long acting GLP-1 RA (liraglutide, semaglutide, albiglutide and dulaglutide[103-106]) in terms of reducing 3 point major adverse cardiovascular endpoints comprised of non-fatal myocardial infarction, non-fatal stroke and cardiovascular mortality this therapeutic option has its merits in treatment of PTDM.

    Presently, there are no clinical trials published regarding GLP 1RA therapy in PTDM. The only studies available are conducted in case series of patients after kidney and pancreas transplant providing enough scientific rationale for this treatment concept in liver PTDM[150-153]. In a study performed by Haldenet al[150]in patients with and without PTDM after kidney transplant GLP infusion in hyperglycemic clamp led to improvement of insulin and normalization of glucagon concentrations.Furthermore, GLP 1RAs also exhibit resistance against toxicity of immunosuppressive drugsin vitro[154]and seem to prevent steroid diabetes by diminishing glucocorticoidinduced glucose metabolism impairment and beta-cell dysfunction in healthy humans[155].

    Since long acting GLP 1RA agonists are eliminated through enzymatic degradation and renaly cleared, drug-drug interactions are avoided which is extremely important in terms of immunosuppressant drug metabolism[156]. However, by delaying gastric emptying, absorption of other drugs could be affected. In a two studies of case series of kidney transplant recipients with PTDM safe co-administration of liraglutide and tacrolimus was reported mitigating, at least partially, concerns regarding absorption interference[152,153].

    One of the major downsides of GLP 1RA therapy are gastrointestinal (GI) side effects which could potentiate a GI disturbances caused by immunosuppressant drugs leading to limited usage of GLP 1 RA in spite of their numerous beneficial effects[157],Table 1.

    USE OF GLP-1RA IN TREATING NAFLD AND POSTTRANSPLANT NAFLD IN LT PATIENTS

    Pharmacokinetic and pharmacodynamic properties of GLP 1 RA seems to be of extreme convenience in LT since none are metabolized by the liver and no dose adjustment is needed[156]. As already mentioned, there is growing body of evidence suggesting beneficial effects of GLP 1RA therapy in patients with NAFLD/NASH affecting not only liver enzymes normalization but also reducing inflammation and progression of fibrosis[122,127,130,131]. There are two different aspects of potential mechanisms of action involving GLP 1RA in post-transplant NAFLD. For one,improvement of metabolic disturbances through induction of weight loss, especially seen during first few weeks after transplantation[158]. Thus, lipogenesis is decreased leading to a reduction in free fatty acid and triglyceride toxic metabolites positively affecting insulin resistance, oxidative stress and inflammation, while increasing insulin secretion initiating changes in gut liver axis which are not completely understood yet[4]. The second relates to direct anti-fibrotic effects independent of metabolic changes recently shown in animal and human studies[159]. Unfortunately there are no clinical studies performed in post-transplant NAFLD/NASH patients,although based on present knowledge this therapeutic approach would be completely justified, Table 1.

    PTDM IN LT PATIENTS AND THE ROLE OF SGLT2i

    SGLT2 inhibitors have recently been recommended as a treatment of choice for patients with diabetes and high cardiovascular risk, which is also a characteristic of patients with PTDM[160]. The evidence of the use of gliflozins in PTDM in LT patients is scarce, but results from animal studies are promising. Rats with tacrolimus-induced diabetes that received empagliflozin had lower glycemia and increased plasma insulin levels[161]. In a case series of patients with post heart transplant diabetes mellitus,empagliflozin reduced weight, and blood pressure[162]. In a small group of kidney recipients, canagliflozin treatment improved glycemia, reduced weight and blood pressure[163]. Recently published study using empagliflozin in a larger population of PTDM patients after kidney transplantation showed improvement of glycemic control compared to placebo, and a concomitant reduction of body weight[164]. Major potential problem with SGLT2 inhibitors in PTDM might be genitourinary infections,considering concurrent immunosuppressive therapy and glycosuria. Up to date collected data, mainly in the kidney transplant patients with PTDM suggests incidence of the GU infections is not higher than that seen in T2DM patients and resolves with usual antibiotics/antifungal treatment[164], Table 1.

    USE OF SGLT2i IN TREATING NAFLD AND POSTTRANSPLANT NAFLD IN LT PATIENTS

    Currently, SGLT2 inhibitors have not the indication of improving NAFLD and dedicated research is mandatory in this evolving field. In several RCTs SGLT2 inhibitors have shown positive effects on NAFLD in patients with T2DM, but the exact mechanisms are still speculative, as is their role in treating post-transplant NAFLD in patients with and without diabetes[165]. SGLT2 inhibitors are cleared by the liver, but pharmacokinetic trials involving patients with mild to moderate hepatic impairment demonstrated their safety and no need for dose adjustments in the setting of liver disease[166]. Besides safety, by reducing liver fat content and hepatocyte injury biomarkers which was shown in several gliflozin RCTs they might prove liver protective and improve NAFLD-associated endoplasmatic reticulum stress and mitochondrial function[91]. Additionally, SGLT2 inhibitors are associated with significant weight loss, especially reduction in fat mass and visceral adipose tissue,which makes them interesting agents in treating post-transplant NAFLD in LT patients. Additionally, they attenuate the renin-angiotensin-aldosteron pathway by inhibition of sodium reabsorption which in theory makes the SGLT2 inhibitors ideal for patients with cirrhosis[165], Table 1.

    CONCLUSION

    In conclusion, pharmacological management of PTDM is further complicated given there are no published randomized clinical trials regarding effectiveness and safety of antihyperglycemic agents. Particular characteristics of PTDM include prodiabetogenic potential of immunosuppressant drugs as well as increased cardiovascular risk due to higher incidence of metabolic disturbances present in post-transplant period both of which could be successfully resolved with GLP 1RA and SGLT2i therapy. Further prospective studies including larger number of patients are needed.

    Considering that currently NASH is one of the main causes of LT and it is associated with metabolic disorders mainly IR, which is a particular problem in transplanted patients, GLP 1 RA and SGLT2i treatment certainly has the potential to influence precisely this bidirectional relationship between PTDM and preexisting liver disease.

    ACKNOWLEDGEMENTS

    The authors would like to thank Hrvojka Dolic for the help with the graphics.

    国国产精品蜜臀av免费| 美女中出高潮动态图| 高清视频免费观看一区二区| 亚洲国产精品一区二区三区在线| 日本vs欧美在线观看视频| 黄色怎么调成土黄色| 99热全是精品| 国产午夜精品一二区理论片| av在线观看视频网站免费| 夫妻午夜视频| 久久人人爽人人片av| 成人综合一区亚洲| 亚洲av日韩在线播放| 日日撸夜夜添| 国产免费视频播放在线视频| 中文字幕制服av| 人人妻人人爽人人添夜夜欢视频| 91aial.com中文字幕在线观看| 一边亲一边摸免费视频| 热99国产精品久久久久久7| 久久人人97超碰香蕉20202| 这个男人来自地球电影免费观看 | 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 人人妻人人澡人人爽人人夜夜| av播播在线观看一区| 男女边吃奶边做爰视频| 久久久久网色| 青春草视频在线免费观看| 全区人妻精品视频| 色吧在线观看| 在线 av 中文字幕| 精品视频人人做人人爽| 久久久亚洲精品成人影院| 国产国拍精品亚洲av在线观看| 国产精品久久久久成人av| 极品少妇高潮喷水抽搐| 亚洲欧美精品自产自拍| 亚洲av福利一区| 亚洲欧美清纯卡通| 美女中出高潮动态图| 午夜福利网站1000一区二区三区| 久久人人爽人人爽人人片va| 秋霞在线观看毛片| 欧美激情国产日韩精品一区| 国产极品粉嫩免费观看在线| videossex国产| av线在线观看网站| 国产精品久久久久久久电影| 有码 亚洲区| 女性被躁到高潮视频| 精品一区二区三卡| 视频在线观看一区二区三区| 国产亚洲最大av| 亚洲欧美一区二区三区国产| 午夜免费男女啪啪视频观看| 午夜av观看不卡| 天美传媒精品一区二区| 香蕉精品网在线| 国产欧美亚洲国产| 亚洲成国产人片在线观看| 国语对白做爰xxxⅹ性视频网站| 啦啦啦啦在线视频资源| av在线app专区| 一区二区日韩欧美中文字幕 | 国产探花极品一区二区| 伊人久久国产一区二区| 日本91视频免费播放| 久久精品aⅴ一区二区三区四区 | 高清在线视频一区二区三区| 精品亚洲成a人片在线观看| 精品一品国产午夜福利视频| 在线天堂中文资源库| 大陆偷拍与自拍| 22中文网久久字幕| 午夜日本视频在线| 美女国产视频在线观看| 美女国产高潮福利片在线看| 亚洲,欧美精品.| 制服诱惑二区| 最后的刺客免费高清国语| 极品少妇高潮喷水抽搐| 亚洲欧美一区二区三区黑人 | a级毛片黄视频| 亚洲国产看品久久| 亚洲av欧美aⅴ国产| 午夜久久久在线观看| 久久久久精品性色| 另类亚洲欧美激情| 少妇被粗大猛烈的视频| 丝袜美足系列| 亚洲国产毛片av蜜桃av| 午夜日本视频在线| 亚洲,一卡二卡三卡| 亚洲美女搞黄在线观看| 免费观看在线日韩| 欧美少妇被猛烈插入视频| 少妇熟女欧美另类| 亚洲性久久影院| 国产 一区精品| 一区二区三区四区激情视频| 午夜福利视频在线观看免费| 天天躁夜夜躁狠狠久久av| 91久久精品国产一区二区三区| 性色av一级| 黄色一级大片看看| 亚洲av福利一区| 九色亚洲精品在线播放| 日韩在线高清观看一区二区三区| 成人国产麻豆网| 国语对白做爰xxxⅹ性视频网站| 日韩视频在线欧美| 国产精品成人在线| 婷婷色综合www| 日韩视频在线欧美| 波多野结衣一区麻豆| 国产成人a∨麻豆精品| 亚洲国产精品国产精品| 国产永久视频网站| 成人18禁高潮啪啪吃奶动态图| 国产精品久久久久久久久免| 国产高清不卡午夜福利| 精品久久国产蜜桃| 亚洲精品国产av蜜桃| 黑丝袜美女国产一区| 国产精品人妻久久久影院| 国产片特级美女逼逼视频| 国产精品人妻久久久久久| 制服诱惑二区| 免费日韩欧美在线观看| 精品少妇黑人巨大在线播放| 亚洲综合色惰| 亚洲欧美日韩另类电影网站| 久久久久久久久久人人人人人人| 777米奇影视久久| 欧美xxxx性猛交bbbb| 欧美+日韩+精品| 国产麻豆69| 国产精品熟女久久久久浪| 男人添女人高潮全过程视频| 视频在线观看一区二区三区| 久久精品国产综合久久久 | 人人妻人人添人人爽欧美一区卜| 又黄又爽又刺激的免费视频.| a级毛片在线看网站| 色视频在线一区二区三区| 黑人巨大精品欧美一区二区蜜桃 | 免费看av在线观看网站| 日本黄大片高清| 伦理电影免费视频| 男女啪啪激烈高潮av片| 久久久久久久精品精品| 久久精品熟女亚洲av麻豆精品| 国产精品偷伦视频观看了| 毛片一级片免费看久久久久| 少妇的逼水好多| 日本午夜av视频| 最后的刺客免费高清国语| 成年动漫av网址| 午夜av观看不卡| 丰满少妇做爰视频| 日韩成人伦理影院| 色婷婷av一区二区三区视频| 少妇人妻精品综合一区二区| 久久女婷五月综合色啪小说| av天堂久久9| 成年av动漫网址| 久久99一区二区三区| 久久影院123| 内地一区二区视频在线| 纵有疾风起免费观看全集完整版| 国产免费视频播放在线视频| kizo精华| 日本vs欧美在线观看视频| 亚洲欧美一区二区三区国产| 最近中文字幕2019免费版| 多毛熟女@视频| 中文字幕亚洲精品专区| 一级片免费观看大全| 久久青草综合色| 国产亚洲av片在线观看秒播厂| 日韩av不卡免费在线播放| 久久99热这里只频精品6学生| 久久久国产欧美日韩av| 波多野结衣一区麻豆| 高清欧美精品videossex| 日韩在线高清观看一区二区三区| 少妇的丰满在线观看| 久久人人爽人人片av| 免费av不卡在线播放| 午夜久久久在线观看| 18禁动态无遮挡网站| 在线看a的网站| 黑人欧美特级aaaaaa片| 成年动漫av网址| 中文字幕人妻熟女乱码| 9热在线视频观看99| 久久精品国产亚洲av涩爱| 国产成人91sexporn| 国产成人aa在线观看| 女人久久www免费人成看片| 亚洲av福利一区| 99热这里只有是精品在线观看| 精品一品国产午夜福利视频| 天堂中文最新版在线下载| 久久久亚洲精品成人影院| av福利片在线| 久久久久人妻精品一区果冻| 最后的刺客免费高清国语| 国产爽快片一区二区三区| 亚洲成av片中文字幕在线观看 | www.av在线官网国产| 国产黄频视频在线观看| 丰满乱子伦码专区| 亚洲四区av| 极品少妇高潮喷水抽搐| 亚洲av电影在线进入| 人人妻人人澡人人看| av卡一久久| 男人舔女人的私密视频| 大香蕉久久成人网| 下体分泌物呈黄色| 肉色欧美久久久久久久蜜桃| 国产免费视频播放在线视频| 欧美+日韩+精品| 精品午夜福利在线看| 欧美 日韩 精品 国产| 永久免费av网站大全| av国产精品久久久久影院| 成年女人在线观看亚洲视频| 久久久久久伊人网av| 麻豆乱淫一区二区| 日本-黄色视频高清免费观看| 天美传媒精品一区二区| kizo精华| √禁漫天堂资源中文www| 久久精品国产a三级三级三级| 2022亚洲国产成人精品| 日韩欧美精品免费久久| 日本黄色日本黄色录像| 国产亚洲欧美精品永久| 精品亚洲乱码少妇综合久久| 久久99精品国语久久久| 97人妻天天添夜夜摸| 国产白丝娇喘喷水9色精品| 多毛熟女@视频| av在线app专区| 亚洲色图 男人天堂 中文字幕 | 99国产综合亚洲精品| 亚洲国产精品一区三区| h视频一区二区三区| www.色视频.com| 成人二区视频| av在线观看视频网站免费| 国产亚洲精品久久久com| 久久久久国产网址| 丰满迷人的少妇在线观看| 国产色爽女视频免费观看| 午夜av观看不卡| 人妻少妇偷人精品九色| 日本免费在线观看一区| 91精品伊人久久大香线蕉| 亚洲人成网站在线观看播放| 久久久国产一区二区| 乱人伦中国视频| 欧美精品一区二区免费开放| 麻豆乱淫一区二区| 亚洲精品乱码久久久久久按摩| videossex国产| 91精品三级在线观看| 色哟哟·www| 精品99又大又爽又粗少妇毛片| 18在线观看网站| 在现免费观看毛片| 日本免费在线观看一区| 国产1区2区3区精品| 18禁国产床啪视频网站| 男女国产视频网站| 两个人免费观看高清视频| 一本—道久久a久久精品蜜桃钙片| 如何舔出高潮| 制服诱惑二区| 免费看av在线观看网站| 国产精品成人在线| 午夜激情av网站| 99视频精品全部免费 在线| 看免费av毛片| 亚洲精品美女久久久久99蜜臀 | 亚洲成色77777| 久久人人爽av亚洲精品天堂| 日韩在线高清观看一区二区三区| 国产片内射在线| 少妇精品久久久久久久| 亚洲av.av天堂| 久热久热在线精品观看| 这个男人来自地球电影免费观看 | 日韩欧美精品免费久久| 久久久久久久久久久免费av| 最近中文字幕高清免费大全6| 免费看不卡的av| 大片电影免费在线观看免费| 精品一区二区三卡| 中文精品一卡2卡3卡4更新| 亚洲精品一区蜜桃| 亚洲欧洲国产日韩| 婷婷成人精品国产| 波多野结衣一区麻豆| 成人黄色视频免费在线看| 亚洲精品日本国产第一区| 夫妻性生交免费视频一级片| 亚洲高清免费不卡视频| 成人免费观看视频高清| 亚洲精品av麻豆狂野| 色5月婷婷丁香| 国产亚洲午夜精品一区二区久久| 久久婷婷青草| 一级a做视频免费观看| 在线观看一区二区三区激情| 亚洲成国产人片在线观看| 婷婷成人精品国产| 亚洲熟女精品中文字幕| 天堂俺去俺来也www色官网| 边亲边吃奶的免费视频| 亚洲国产色片| 人成视频在线观看免费观看| 久久久久精品性色| 22中文网久久字幕| 一二三四在线观看免费中文在 | 午夜福利视频精品| 色94色欧美一区二区| 午夜免费鲁丝| 久久久久精品人妻al黑| 天美传媒精品一区二区| 日韩,欧美,国产一区二区三区| 亚洲情色 制服丝袜| 国产精品人妻久久久久久| 有码 亚洲区| 亚洲国产看品久久| 精品久久国产蜜桃| 少妇被粗大的猛进出69影院 | 久久久国产欧美日韩av| 亚洲精品乱久久久久久| 少妇精品久久久久久久| 国产男人的电影天堂91| 国产淫语在线视频| 国产成人精品婷婷| 亚洲丝袜综合中文字幕| 国国产精品蜜臀av免费| 免费看不卡的av| www.熟女人妻精品国产 | 久久99热这里只频精品6学生| kizo精华| 青青草视频在线视频观看| 国产精品不卡视频一区二区| 天堂8中文在线网| 国产毛片在线视频| 欧美日韩视频高清一区二区三区二| 亚洲人成网站在线观看播放| 精品第一国产精品| 欧美人与善性xxx| 9色porny在线观看| 日韩,欧美,国产一区二区三区| xxxhd国产人妻xxx| 免费大片黄手机在线观看| 久久99热这里只频精品6学生| 欧美激情国产日韩精品一区| 高清不卡的av网站| 久久女婷五月综合色啪小说| 亚洲欧美清纯卡通| 亚洲精品aⅴ在线观看| 最近手机中文字幕大全| 精品少妇黑人巨大在线播放| 日韩三级伦理在线观看| 国产精品久久久久久精品电影小说| 亚洲精华国产精华液的使用体验| 亚洲精品自拍成人| 黑人欧美特级aaaaaa片| 国产亚洲精品第一综合不卡 | 成年人午夜在线观看视频| 亚洲成av片中文字幕在线观看 | 国产精品国产三级专区第一集| 日日摸夜夜添夜夜爱| 两个人免费观看高清视频| 久久久久精品久久久久真实原创| av女优亚洲男人天堂| av在线老鸭窝| 亚洲美女视频黄频| 最近的中文字幕免费完整| 亚洲人成77777在线视频| 国产精品三级大全| 天堂俺去俺来也www色官网| 这个男人来自地球电影免费观看 | 老司机亚洲免费影院| 亚洲一码二码三码区别大吗| 久久久久精品性色| 国产精品国产三级专区第一集| 韩国高清视频一区二区三区| 国产一区二区在线观看日韩| 极品少妇高潮喷水抽搐| 啦啦啦在线观看免费高清www| 男女无遮挡免费网站观看| 少妇的逼好多水| 午夜免费观看性视频| 欧美另类一区| 99re6热这里在线精品视频| av在线播放精品| 久久精品人人爽人人爽视色| 欧美人与性动交α欧美软件 | 亚洲精品中文字幕在线视频| 欧美bdsm另类| 国产亚洲精品第一综合不卡 | 欧美人与善性xxx| 亚洲 欧美一区二区三区| 国产一区二区激情短视频 | 国产亚洲精品第一综合不卡 | 欧美激情国产日韩精品一区| 毛片一级片免费看久久久久| 午夜福利在线观看免费完整高清在| 国产片特级美女逼逼视频| 日韩av不卡免费在线播放| 青春草国产在线视频| 欧美精品一区二区免费开放| 韩国精品一区二区三区 | 18禁国产床啪视频网站| 一区二区三区四区激情视频| 99国产综合亚洲精品| 老司机亚洲免费影院| 精品人妻偷拍中文字幕| 妹子高潮喷水视频| 久久精品久久久久久噜噜老黄| 高清毛片免费看| av免费在线看不卡| 在线观看免费视频网站a站| 狂野欧美激情性xxxx在线观看| 欧美激情国产日韩精品一区| 久久午夜福利片| 制服丝袜香蕉在线| 秋霞在线观看毛片| 中文字幕人妻熟女乱码| 国产色爽女视频免费观看| 有码 亚洲区| 国产精品熟女久久久久浪| 久久99热6这里只有精品| 99视频精品全部免费 在线| 午夜免费鲁丝| 日本欧美视频一区| 五月伊人婷婷丁香| 国产精品99久久99久久久不卡 | 9热在线视频观看99| 熟女电影av网| 国产成人免费无遮挡视频| 久久久久久久久久成人| 国产男人的电影天堂91| 在线观看人妻少妇| 五月伊人婷婷丁香| 欧美精品亚洲一区二区| 成年美女黄网站色视频大全免费| 黄色毛片三级朝国网站| 另类亚洲欧美激情| 日韩中文字幕视频在线看片| 久热久热在线精品观看| 一级,二级,三级黄色视频| 亚洲高清免费不卡视频| 十八禁网站网址无遮挡| 美女xxoo啪啪120秒动态图| 亚洲第一区二区三区不卡| 精品少妇久久久久久888优播| 乱码一卡2卡4卡精品| 男人操女人黄网站| 亚洲精品日本国产第一区| 国产免费现黄频在线看| 久久人人爽av亚洲精品天堂| 国产不卡av网站在线观看| 欧美精品av麻豆av| 国产又爽黄色视频| 自拍欧美九色日韩亚洲蝌蚪91| 久久久久久人人人人人| 精品福利永久在线观看| 在线 av 中文字幕| 中文字幕另类日韩欧美亚洲嫩草| 中文字幕av电影在线播放| 美女中出高潮动态图| 亚洲一级一片aⅴ在线观看| 在线观看人妻少妇| 五月伊人婷婷丁香| 九色亚洲精品在线播放| 亚洲av中文av极速乱| 亚洲av免费高清在线观看| 国产男女超爽视频在线观看| 99久久综合免费| 在线天堂中文资源库| 2018国产大陆天天弄谢| 久久国产精品男人的天堂亚洲 | 涩涩av久久男人的天堂| av片东京热男人的天堂| 精品亚洲乱码少妇综合久久| 日本色播在线视频| 人妻少妇偷人精品九色| 国产极品天堂在线| 国产日韩欧美视频二区| 日本-黄色视频高清免费观看| 久久国产亚洲av麻豆专区| 国产成人精品福利久久| 亚洲av福利一区| 成年动漫av网址| 2018国产大陆天天弄谢| 丝袜喷水一区| 成人国语在线视频| 十八禁高潮呻吟视频| 人人妻人人澡人人看| 免费黄网站久久成人精品| 视频区图区小说| 九九爱精品视频在线观看| 色婷婷av一区二区三区视频| 午夜精品国产一区二区电影| 免费播放大片免费观看视频在线观看| 精品99又大又爽又粗少妇毛片| 十分钟在线观看高清视频www| 久久久久久久国产电影| 99热网站在线观看| 内地一区二区视频在线| 久久99精品国语久久久| 亚洲精品第二区| 蜜臀久久99精品久久宅男| 99热全是精品| 国产永久视频网站| 三级国产精品片| 成人手机av| 99热这里只有是精品在线观看| 天天操日日干夜夜撸| 国内精品宾馆在线| 亚洲一码二码三码区别大吗| 狂野欧美激情性bbbbbb| 1024视频免费在线观看| 久久99热6这里只有精品| 婷婷色综合大香蕉| 黄色 视频免费看| 五月伊人婷婷丁香| 女人被躁到高潮嗷嗷叫费观| 亚洲欧洲国产日韩| 天天躁夜夜躁狠狠躁躁| 国产国语露脸激情在线看| 亚洲国产精品国产精品| av免费在线看不卡| 国产亚洲av片在线观看秒播厂| 国产男女内射视频| 尾随美女入室| 久久精品久久精品一区二区三区| 波野结衣二区三区在线| 一本大道久久a久久精品| 国产永久视频网站| 免费看av在线观看网站| 欧美人与性动交α欧美精品济南到 | 免费观看a级毛片全部| 国产在线一区二区三区精| 亚洲综合色网址| 欧美激情 高清一区二区三区| 国产片内射在线| 91精品三级在线观看| 日韩欧美精品免费久久| 久久人妻熟女aⅴ| 国产亚洲精品久久久com| 人成视频在线观看免费观看| 建设人人有责人人尽责人人享有的| 久久精品久久久久久噜噜老黄| 精品亚洲乱码少妇综合久久| 午夜激情久久久久久久| 蜜桃在线观看..| 亚洲色图综合在线观看| 插逼视频在线观看| 国产精品久久久久久精品电影小说| av在线观看视频网站免费| 日韩一区二区三区影片| 99热国产这里只有精品6| 高清在线视频一区二区三区| 国产国拍精品亚洲av在线观看| 一区二区日韩欧美中文字幕 | 久久精品国产亚洲av天美| 国产一区亚洲一区在线观看| 午夜视频国产福利| 中文字幕最新亚洲高清| 国产成人精品福利久久| 中文字幕精品免费在线观看视频 | 国产精品熟女久久久久浪| 亚洲第一区二区三区不卡| 五月天丁香电影| 天天操日日干夜夜撸| 人妻少妇偷人精品九色| 午夜av观看不卡| 午夜福利视频在线观看免费| 又粗又硬又长又爽又黄的视频| 97超碰精品成人国产| 少妇猛男粗大的猛烈进出视频| 国产成人精品福利久久| 好男人视频免费观看在线| 99视频精品全部免费 在线| 男人爽女人下面视频在线观看| 男女啪啪激烈高潮av片| 国产精品久久久久久精品古装| 久久这里只有精品19| 日韩视频在线欧美| 成人18禁高潮啪啪吃奶动态图| 在线天堂中文资源库| 春色校园在线视频观看| 久久久亚洲精品成人影院| 国产成人欧美| 99久久中文字幕三级久久日本| 久久婷婷青草| 黄色怎么调成土黄色| 美女脱内裤让男人舔精品视频| 久久久久精品性色| 香蕉国产在线看| 乱码一卡2卡4卡精品| 激情五月婷婷亚洲| 亚洲中文av在线| 久久久久网色|